Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

Citation

Published Version
doi:10.18632/oncotarget.10398

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRespos:32072212

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRespos: dash.current.terms-of-use#LAA
Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival

Kosuke Mima1,*, Jonathan A. Nowak2,*, Zhi Rong Qian1,*, Yin Cao3,4,5, Mingyang Song3,4,5, Yohei Masugi1, Yan Shi1, Annacarolina da Silva1, Mancang Gu1, Wanwan Li1, Tsuyoshi Hamada1, Xuehong Zhang6, Kana Wu5,6, Jeffrey A. Meyerhardt1, Hideo Baba7, Edward L. Giovannucci5,6, Andrew T. Chan3,4,6,*, Charles S. Fuchs1,6,*, Shuji Ogino1,2,8,* , Reiko Nishihara1,5,*

1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
2Division of MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
3Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
4Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA
5Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
6Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
7Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan
8Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

*These authors have contributed equally to this work

Correspondence to:
Shuji Ogino, email: shuji_ogino@dfci.harvard.edu
Reiko Nishihara, email: mishihara@hsph.harvard.edu

Keywords: epigenetics, left-sided, molecular pathological epidemiology, prognosis, right-sided

Received: January 30, 2016    Accepted: June 17, 2016    Published: July 04, 2016

ABSTRACT

Colorectal tumors arise with genomic and epigenomic alterations through interactions between neoplastic cells, immune cells, and microbiota that vary along the proximal to distal axis of colorectum. Long interspersed nucleotide element-1 (LINE-1) hypomethylation in colorectal cancer has been associated with worse clinical outcome. Utilizing 1,317 colon and rectal carcinoma cases in two U.S.-nationwide prospective cohort studies, we examined patient survival according to LINE-1 methylation level stratified by tumor location. Cox proportional hazards model was used to assess a statistical interaction between LINE-1 methylation level and tumor location in colorectal cancer-specific mortality analysis, controlling for potential confounders including microsatellite instability, CpG island methylator phenotype, and KRAS, BRAF, and PIK3CA mutations. A statistically significant interaction was found between LINE-1 methylation level and tumor location in colorectal cancer-specific mortality analysis (Pinteraction = 0.011). The association of LINE-1 hypomethylation with higher colorectal cancer-specific mortality was stronger in proximal colon cancers (multivariable hazard ratio [HR], 1.66; 95% confidence interval [CI], 1.21 to 2.28) than in distal colon cancers (multivariable HR, 1.18; 95% CI, 0.81 to 1.72) or rectal cancers (multivariable HR, 0.87; 95% CI, 0.57 to 1.34). Our data suggest the interactive effect of LINE-1 methylation level and colorectal cancer location on clinical outcome.

INTRODUCTION

Evidence suggests that colorectal tumors arise with sets of genomic and epigenomic alterations through interactions between neoplastic cells, immune cells, and microbiota that vary along the proximal to distal axis of colorectum [1–6]. Consistent with a continuous change in the intestinal microbiota and luminal contents along...
the bowel subsites, host immunity against colorectal tumors and proportions of colorectal cancers with specific molecular features of colorectal cancer such as microsatellite instability (MSI), high-level CpG island methylator phenotype (CIMP), and BRAF and PIK3CA mutations change along the bowel subsites [7–12].

Methylation status of the long interspersed nucleotide element-1 (LINE-1), which constitutes approximately 18% of the entire human genome, serves as a surrogate for overall cellular DNA methylation status [13, 14]. The genome-wide DNA hypomethylation has been associated with an increased chromosomal instability that may cause low-level antitumor immunity in colorectal cancer [15–20]. In fact, LINE-1 hypomethylation in colorectal cancer has been associated with a lower density of T cells in tumor tissue and worse clinical outcome [21–23]. Studies have shown that the prognostic association of tumor LINE-1 methylation level in colorectal cancer differs by MSI status [24, 25]. We hypothesized that the prognostic association of LINE-1 hypomethylation in colorectal cancer might differ by tumor location.

To test this hypothesis, we utilized resources of 1,317 colorectal cancer cases in two U.S.-nationwide prospective cohort studies (the Nurses’ Health Study [NHS] and the Health Professionals Follow-up Study [HPFS]), and examined the interactive association of LINE-1 methylation level and tumor location in colorectal cancer mortality analysis, controlling for potential confounders including major molecular features of colorectal cancer. A better understanding of the prognostic association of tumor LINE-1 hypomethylation according to colorectal cancer location may offer new insights into the pathogenesis of colorectal cancer.

RESULTS

Tumor LINE-1 methylation level and colorectal cancer location

We measured tumor LINE-1 methylation level (ranging from 23.1 to 93.8% of 0 to 100% scale; mean 63.4%; standard deviation 9.8%) among 1,317 colon and rectal cancer cases within the NHS and the HPFS. Table 1 summarizes clinical, pathological, and tumor molecular features according to tumor LINE-1 methylation level in colorectal cancer. Of the 1,317 cases, 621 (47%) had proximal colon cancer, 409 (31%) had distal colon cancer, and 287 (22%) had rectal cancer. Low-level tumor LINE-1 methylation was associated with higher pN stage and metastatic disease, and inversely associated with poor tumor differentiation, MSI-high, MLH1 hypermethylation, CIMP-high, and BRAF mutation (P ≤ 0.003 with the adjusted α level of 0.003 for multiple hypothesis testing).

Clinical, pathological, and tumor molecular features according to tumor LINE-1 methylation level in proximal colon, distal colon, and rectal cancers are summarized in Supplementary Table S1.

Tumor LINE-1 hypomethylation and patient survival according to colorectal cancer location

We examined the relationship between tumor LINE-1 methylation level and patient survival according to colorectal cancer location (Table 2). In the 1,317 colorectal cancer cases, there were 717 deaths, including 382 colorectal cancer-specific deaths, during a median patient follow-up of 12.0 years (interquartile range: 8.0 to 16.6) among censored cases.

For our primary hypothesis testing, we found a statistically significant interaction between LINE-1 methylation level and tumor location in colorectal cancer-specific mortality analysis (P_interaction = 0.011; Table 2). Hazard ratio (HR) of colorectal cancer-specific mortality for 20% decrease in tumor LINE-1 methylation level was higher in proximal colon cancers (multivariable HR, 1.66; 95% confidence interval [CI], 1.21 to 2.28) than in distal colon cancers (multivariable HR, 1.18; 95% CI, 0.81 to 1.72) or rectal cancers (multivariable HR, 0.87; 95% CI, 0.57 to 1.34) (Table 2). In the Kaplan-Meier analysis and the log-rank test (Figure 1), tumor LINE-1 hypomethylation was associated with higher colorectal cancer-specific mortality in proximal colon cancer (P < 0.0001 for trend), but not in distal colon cancer (P = 0.12 for trend) or rectal cancer (P = 0.60 for trend).

In the secondary analysis, a similar interactive association between tumor LINE-1 methylation level and colorectal cancer location was observed in overall mortality analysis (P_interaction = 0.002; Table 2). Tumor LINE-1 hypomethylation was associated with higher overall mortality in proximal colon cancer (for 20% decrease in tumor LINE-1 methylation level: multivariable HR, 1.40; 95% CI, 1.10 to 1.78), whereas tumor LINE-1 methylation level were not significantly associated with overall mortality in distal colon cancer (for 20% decrease in tumor LINE-1 methylation level: multivariable HR, 1.14; 95% CI, 0.86 to 1.50) or rectal cancer (for 20% decrease in tumor LINE-1 methylation level: multivariable HR, 0.72; 95% CI, 0.52 to 1.00).

Tumor LINE-1 hypomethylation and patient survival in strata of colorectal tumor location and MSI status

Given our previous study showing the interactive association between tumor LINE-1 methylation level and MSI status in relation to colorectal cancer mortality [25], we conducted an exploratory analysis to examine the relationship between tumor LINE-1 hypomethylation and patient survival in strata of colorectal cancer location and MSI status (Table 3). In proximal colon cancers, tumor LINE-1 hypomethylation appeared to be associated with
Table 1: Clinical, pathological, and tumor molecular features according to tumor LINE-1 methylation level in colorectal cancer

<table>
<thead>
<tr>
<th>Characteristica</th>
<th>Total No. (n = 1,317)</th>
<th>Tumor LINE-1 methylation level</th>
<th>P valuemb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>High (≥65%) (n = 579)</td>
<td>Intermediate (55-64.9%) (n = 496)</td>
</tr>
<tr>
<td>Mean age ± SD (year)</td>
<td>68.9 ± 8.8</td>
<td>69.9 ± 8.6</td>
<td>68.7 ± 8.7</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>593 (45%)</td>
<td>255 (44%)</td>
<td>214 (43%)</td>
</tr>
<tr>
<td>Women</td>
<td>724 (55%)</td>
<td>324 (56%)</td>
<td>282 (57%)</td>
</tr>
<tr>
<td>Year of diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prior to 1995</td>
<td>468 (36%)</td>
<td>162 (28%)</td>
<td>202 (40%)</td>
</tr>
<tr>
<td>1996 to 2000</td>
<td>402 (30%)</td>
<td>157 (27%)</td>
<td>147 (30%)</td>
</tr>
<tr>
<td>2001 to 2008</td>
<td>447 (34%)</td>
<td>260 (45%)</td>
<td>147 (30%)</td>
</tr>
<tr>
<td>Family history of colorectal cancer in a first-degree relative</td>
<td>0.35</td>
<td>0.004</td>
<td>0.002</td>
</tr>
<tr>
<td>Absent</td>
<td>1,048 (80%)</td>
<td>471 (81%)</td>
<td>391 (79%)</td>
</tr>
<tr>
<td>Present</td>
<td>264 (20%)</td>
<td>107 (19%)</td>
<td>102 (21%)</td>
</tr>
<tr>
<td>Tumor location</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proximal colon</td>
<td>621 (47%)</td>
<td>301 (52%)</td>
<td>224 (45%)</td>
</tr>
<tr>
<td>Distal colon</td>
<td>409 (31%)</td>
<td>151 (26%)</td>
<td>166 (34%)</td>
</tr>
<tr>
<td>Rectum</td>
<td>287 (22%)</td>
<td>127 (22%)</td>
<td>106 (21%)</td>
</tr>
<tr>
<td>Tumor differentiation</td>
<td>0.002</td>
<td>0.002</td>
<td>0.002</td>
</tr>
<tr>
<td>Well to moderate</td>
<td>1,178 (90%)</td>
<td>501 (87%)</td>
<td>461 (94%)</td>
</tr>
<tr>
<td>Poor</td>
<td>131 (10%)</td>
<td>74 (13%)</td>
<td>32 (6.5%)</td>
</tr>
<tr>
<td>pT stage (depth of tumour invasion)</td>
<td>0.003</td>
<td>0.003</td>
<td>0.003</td>
</tr>
<tr>
<td>pT1 (submucosa)</td>
<td>143 (12%)</td>
<td>62 (12%)</td>
<td>63 (14%)</td>
</tr>
<tr>
<td>pT2 (muscularis propria)</td>
<td>249 (21%)</td>
<td>115 (22%)</td>
<td>90 (19%)</td>
</tr>
<tr>
<td>pT3 (subserosa)</td>
<td>757 (62%)</td>
<td>327 (62%)</td>
<td>288 (62%)</td>
</tr>
<tr>
<td>pT4 (serosa or other organs)</td>
<td>64 (5.3%)</td>
<td>26 (4.9%)</td>
<td>23 (5.0%)</td>
</tr>
<tr>
<td>pN stage (number of positive lymph nodes)</td>
<td>0.003</td>
<td>0.003</td>
<td>0.003</td>
</tr>
<tr>
<td>pN0 (0)</td>
<td>740 (63%)</td>
<td>348 (68%)</td>
<td>280 (62%)</td>
</tr>
<tr>
<td>pN1 (1-3)</td>
<td>268 (23%)</td>
<td>108 (21%)</td>
<td>105 (23%)</td>
</tr>
<tr>
<td>pN2 (≥4)</td>
<td>163 (14%)</td>
<td>56 (11%)</td>
<td>65 (15%)</td>
</tr>
<tr>
<td>TNM stagec</td>
<td>0.0001</td>
<td>0.0001</td>
<td>0.0001</td>
</tr>
<tr>
<td>I</td>
<td>308 (26%)</td>
<td>141 (27%)</td>
<td>124 (27%)</td>
</tr>
<tr>
<td>II</td>
<td>385 (32%)</td>
<td>186 (36%)</td>
<td>141 (31%)</td>
</tr>
</tbody>
</table>

(Continued)
higher colorectal cancer-specific mortality not only in MSI-high cancers (for 20% decrease in tumor LINE-1 methylation level: multivariable HR, 6.14; 95% CI, 2.27 to 16.6) but also in MSI-low/MSS cancers (for 20% decrease in tumor LINE-1 methylation level: multivariable HR, 1.44; 95% CI, 1.04 to 2.01).

**DISCUSSION**

We conducted this study to test the hypothesis that the prognostic association of tumor LINE-1 hypomethylation might differ by colorectal cancer location. Utilizing the database of 1,317 colorectal cancer cases in the two U.S.-nationwide prospective cohort studies, we found a statistically significant interactive association of tumor LINE-1 methylation level and tumor location in colorectal cancer mortality analysis. The adverse prognostic association of tumor LINE-1 hypomethylation was stronger in proximal colon cancers than in distal colorectal cancers.

Colorectal cancers are a heterogeneous group of diseases that result from the accumulation of differing sets...
of genomic and epigenomic alterations, and tumor-host interactions and, hence, research on tumor biomarkers is important for clinical medicine and public health [26–32]. Few studies have considered colorectal cancer location in evaluating clinical outcome by tumor LINE-1 methylation level. In 76 patients with stage III proximal colon cancer, a lower tumor LINE-1 methylation level is associated with poor disease-free survival [23]. In 94 patients with stage I and II rectal cancer, a lower tumor LINE-1 methylation level is associated with poor recurrence-free and overall survival [33]. However, these previous studies were limited by small sample sizes, and did not examine the interactive association of tumor LINE-1 methylation level and tumor location with clinical outcome. By utilizing a large collection (n = 1,317) of colorectal cancer cases, our population-based data support the interactive association of tumor LINE-1 methylation level and tumor location in colorectal cancer mortality analysis.

Exact mechanisms by which colorectal tumors that exhibit LINE-1 hypomethylation have been associated with aggressive tumor behavior remain uncertain. It has been known that colorectal cancers develop through the accumulation of genetic and epigenetic alterations, influenced by microbial and other environmental exposures and host responses to the exposures [34–39].

Table 2: Tumor LINE-1 hypomethylation and patient survival according to colorectal cancer location

<table>
<thead>
<tr>
<th>No. of cases</th>
<th>Colorectal cancer-specific mortality</th>
<th>Overall mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of events</td>
<td>Univariable HR (95% CI)</td>
</tr>
<tr>
<td>Proximal colon cancer</td>
<td>621</td>
<td>176</td>
</tr>
<tr>
<td>Distal colon cancer</td>
<td>409</td>
<td>111</td>
</tr>
<tr>
<td>Rectal cancer</td>
<td>287</td>
<td>95</td>
</tr>
</tbody>
</table>

CI, confidence interval; HR, hazard ratio; LINE-1, long interspersed nucleotide element-1.

* The multivariable Cox regression model initially included sex, age, year of diagnosis, family history of colorectal cancer in parent or sibling, disease stage, tumor differentiation, microsatellite instability, CpG island methylator phenotype, and KRAS, BRAF, and PIK3CA mutations. A backward elimination with a threshold of P = 0.05 was used to select variables in the final models.

<sup>b</sup> P value was calculated by the Wald test (two-sided).

<sup>c</sup> P<sub>interaction</sub> values (two-sided) were calculated by the Wald test on the cross-product term of tumor LINE-1 methylation level as a continuous variable and colorectal cancer location as an ordinal variable (proximal colon [1], distal colon [2], and rectum [3]).
length of the colorectum [7], suggesting effects of gut contents and microbiota on colorectal tumorigenesis [40]. It is conceivable that tumor-host interactions in the tumor microenvironment including immune response and inflammation might influence the progression of colorectal tumors that exhibit LINE-1 hypomethylation. An increasing body of evidence suggests that microbiota can influence host immunity, and that microbiota, luminal contents, and colonic mucosal immunity may change from the proximal to distal colorectal segments [5, 6, 12, 41–44], future investigations are necessary to examine effects of microbiota on colorectal tumor progression.

Studies have shown that tumor LINE-1 hypomethylation in colorectal cancer is inversely associated with MSI-high, and that the prognostic association of tumor LINE-1 hypomethylation in colorectal cancer is stronger in MSI-high colorectal cancers than in MSS colorectal cancers [24, 25, 45–47], suggesting a complex biological interaction between MSI and LINE-1 hypomethylation in colorectal tumor progression. MSI-high colorectal cancers have been characterized by numerous somatic mutations [48], which might interact with genomic DNA methylation. Future studies are needed to clarify the underlying mechanisms of the association between tumor LINE-1 methylation and MSI status in colorectal cancer progression.

There are biological and clinical differences between colon and rectal cancers including treatment approaches and metastatic pattern [49]. Multiple studies have demonstrated that proportions of colorectal cancers with specific molecular features such as MSI, high-level CIMP, and BRAF and PIK3CA mutations gradually increase along the bowel subsites from rectum to ascending colon [7–9]. Hence, we included both colon and rectal carcinoma cases in the current study. This continuum model is a more advanced model than the simple colon-vs-rectum dichotomy model, because a continuous difference (along the colorectum) will surely lead to a difference in the dichotomy model. We have examined proximal colon vs. distal colon vs. rectum, considering statistical power. Future studies with larger sample size are needed to investigate the prognostic significance of tumor molecular features in the detailed colorectal cancer subsites.

Previous studies have shown that tumor LINE-1 hypomethylation in colorectal cancer is associated with worse clinical outcome, and that LINE-1 hypomethylated colorectal cancers are associated with young age of onset and a family history of colorectal cancer [21, 47, 50]. These findings suggest that LINE-1 methylation level may serve as a potential tumor biomarker for prognosis as well as for familial cancer risk assessment. In addition, our current study found that the adverse prognostic association of tumor LINE-1 hypomethylation was stronger in proximal colon cancers than in distal colorectal cancers. Our current data may help us further stratify patients with colorectal cancer into more individualized prognostic groups based on tumor location, and can guide future mechanistic studies.

We acknowledge limitations of our current study. First, data on cancer recurrence were limited in the two

Figure 1: Kaplan-Meier curves for colorectal cancer-specific survival according to tumor LINE-1 methylation level in proximal colon cancer (A), distal colon cancer (B), and rectal cancer (C). P value was calculated by the log-rank test for trend (two-sided). The tables (bottom) show the number of patients who remained alive and at risk of death at each time point after the diagnosis of colorectal cancer.
Table 3: Tumor LINE-1 hypomethylation and patient survival according to colorectal cancer location and MSI status

<table>
<thead>
<tr>
<th></th>
<th>No. of cases</th>
<th>Colorectal cancer-specific mortality</th>
<th>Overall mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of events</td>
<td>Univariable HR (95% CI)</td>
<td>Multivariable HR (95% CI)</td>
</tr>
<tr>
<td>MSI-low/MSS proximal colon cancer</td>
<td>LINE-1 hypomethylation (20% decrease as a unit)</td>
<td>440 153</td>
<td>1.77 (1.26-2.50)</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>0.001</td>
<td>0.030</td>
</tr>
<tr>
<td>MSI-high proximal colon cancer</td>
<td>LINE-1 hypomethylation (20% decrease as a unit)</td>
<td>181 23</td>
<td>4.51 (1.78-11.4)</td>
</tr>
<tr>
<td>MSI-low/MSS distal colon cancer</td>
<td>LINE-1 hypomethylation (20% decrease as a unit)</td>
<td>388 108</td>
<td>1.21 (0.84-1.76)</td>
</tr>
<tr>
<td>MSI-high distal colon cancer</td>
<td>LINE-1 hypomethylation (20% decrease as a unit)</td>
<td>21 3</td>
<td>3.05 (0.74-12.6)</td>
</tr>
<tr>
<td>Rectal cancer</td>
<td>LINE-1 hypomethylation (20% decrease as a unit)</td>
<td>287 95</td>
<td>0.92 (0.60-1.40)</td>
</tr>
</tbody>
</table>

CI, confidence interval; HR, hazard ratio; LINE-1, long interspersed nucleotide element-1; MSI, microsatellite instability; MSS, microsatellite stable.

* The multivariable Cox regression model initially included sex, age, year of diagnosis, family history of colorectal cancer in parent or sibling, disease stage, tumor differentiation, CpG island methylator phenotype, and KRAS, BRAF, and PIK3CA mutations. A backward elimination with a threshold of \( P = 0.05 \) was used to select variables in the final models.

* *P value was calculated by the Wald test (two-sided).
cohort studies, the NHS (121,701 women enrolled in 1976) [57, 58].

Study population

We utilized the database of colon and rectal carcinoma cases in two U.S.-nationwide prospective cohort studies, the NHS (121,701 women enrolled in 1976) and the HPFS (51,529 men enrolled in 1986) [57, 58].

Assessment of tumor location

DNA was extracted from archival colorectal cancer tissue blocks. We performed bisulfite treatment of DNA, polymerase chain reaction (PCR), and a pyrosequencing assay to measure tumor LINE-1 methylation levels after assay validation [59]. We primarily used tumor LINE-1 methylation level as a continuous variable (20% decrease as a unit) in survival analyses. When we displayed tumor LINE-1 methylation level in relation to clinical, pathological, and tumor molecular features (Table 1), we categorized tumor LINE-1 methylation levels into low (<55% methylation) vs. intermediate (55-64.9% methylation) vs. high (≥65% methylation) to keep consistency with our previous studies [25, 50].

Analysis of MSI, CIMP, and KRAS, BRAF, and PIK3CA mutations

MSI status was analyzed with use of 10 microsatellite markers (D2S123, D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56, D18S67; and
D18S487) as previously described [60]. We defined MSI-high as the presence of instability in ≥30% of the markers, and MSI-low/microsatellite stable (MSS) as instability in <30% of the markers. Methylation analysis of eight promoter CpG islands specific for CIMP (CACNA1G, CDKN2A, CRAPBP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1) was performed as previously described [61, 62]. PCR and pyrosequencing assay targeted for KRAS (codons 12, 13, 61, and 146) [63, 64], BRAF (codon 600) [60], and PIK3CA (exons 9 and 20) [65, 66] were performed as previously described.

Statistical analysis

All statistical analyses were conducted using SAS (version 9.3, SAS Institute, Cary, NC) and all $P$ values were two-sided. Our primary hypothesis testing was a statistical interaction of tumor LINE-1 methylation level and colorectal cancer location in colorectal cancer-specific mortality analysis. Overall mortality was a secondary outcome. The statistical interaction was assessed by the Wald test on the cross-product term of tumor LINE-1 methylation level as a continuous variable and colorectal cancer location as an ordinal variable (proximal colon [1], distal colon [2], and rectum [3]) in a Cox proportional hazards regression model. A two-sided $\alpha$ level was set at 0.05 for our primary hypothesis testing. For a secondary or exploratory analysis, we adjusted the two-sided $\alpha$ level by simple Bonferroni correction for multiple hypothesis testing, in addition to the use of the two-sided $\alpha$ level of 0.05 for our primary hypothesis testing.

For analyses of colorectal cancer-specific mortality, deaths as a result of other causes were censored. The Kaplan-Meier method was used to describe the distribution of colorectal cancer-specific survival, and the log-rank test for trend was performed to assess a linear trend in survival probability across the ordinal categories (high [1] vs. intermediate [2] vs. low [3]) of tumor LINE-1 methylation level. To control for confounders, we used multivariable Cox proportional hazards regression models. In addition to the tumor LINE-1 hypomethylation variable (continuous; 20% decrease as a unit), the multivariable model initially included sex, age at diagnosis (continuous), year of diagnosis (continuous), family history of colorectal cancer in a first-degree relative (present vs. absent), disease stage (I/II vs. III/IV), tumor differentiation (well to moderate vs. poor), MSI (high vs. MSI-low/MSS), CIMP (high vs. low/negative), KRAS (mutant vs. wild-type), BRAF (mutant vs. wild-type), and PIK3CA (mutant vs. wild-type). A single analysis model could assess the prognostic association of tumor LINE-1 hypomethylation in each stratum of colorectal cancer location, using a reparameterization of the interaction term (of tumor LINE-1 hypomethylation and colorectal cancer location) as previously described [25, 57]. A backward elimination was carried out with $P = 0.05$ as a threshold, to select variables for the final model. For cases with missing information in any of the categorical covariates (family history of colorectal cancer in a first-degree relative [0.4%], disease stage [8.7%], tumor differentiation [0.6%], MSI [2.8%], CIMP [4.9%], KRAS [5.2%], BRAF [2.1%], and PIK3CA [8.7%]), we included these cases in the majority category of a given covariate to minimize the number of variables in the multivariable Cox models. We confirmed that excluding the cases with missing information in any of the covariates did not substantially alter results (data not shown). The proportionality of hazards assumption was assessed by a time-varying covariate, using an interaction term of colorectal cancer-specific survival and tumor LINE-1 methylation level ($P = 0.97$).

All univariable analyses for associations of tumor LINE-1 methylation level with clinical, pathological, and tumor molecular features in colorectal cancer, and these associations according to proximal colon, distal colon, and rectal cancer were considered as secondary exploratory analyses. Given the 13 covariates in overall colorectal cancer and the 12 covariates in each of the three cancer locations, we adjusted the two-sided $\alpha$ level to 0.003 (= 0.05/15) by simple Bonferroni correction for multiple hypothesis testing. To assess associations between categorical variables, the chi-square test was performed. To compare mean age, an analysis of variance assuming equal variances was performed.

Abbreviations

CI, confidence interval; CIMP, CpG island methylator phenotype; HPFS, Health Professionals Follow-up Study; HR, hazard ratio; LINE-1, long interspersed nucleotide element-1; MSI, microsatellite instability; MSS, microsatellite stable; NHS, Nurses’ Health Study; PCR, polymerase chain reaction; SD, standard deviation.

Use of standardized official symbols

We use HUGO (Human Genome Organisation)-approved official symbols for genes and gene products, including BRAF, CACNA1G, CDKN2A, CRAPBP1, IGF2, KRAS, MLH1, NEUROG1, PIK3CA, RUNX3, and SOCS1; all of which are described at www.genenames.org. Gene names are italicized, and gene product names are non-italicized.

ACKNOWLEDGMENTS

We would like to thank the participants and staff of the Nurses’ Health Study and the Health Professionals Follow-up Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN,
TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.

CONFLICTS OF INTEREST

Andrew T. Chan previously served as a consultant for Bayer Healthcare, Millennium Pharmaceuticals, Pozen Inc, and Pfizer Inc. This study was not funded by Bayer Healthcare, Millennium Pharmaceuticals, Pozen Inc, or Pfizer Inc. No other conflict of interest exists. The other authors declare that they have no conflicts of interest.

GRANT SUPPORT

This work was supported by U.S. National Institutes of Health (NIH) grants [P01 CA87969 to M.J. Stampfer; UM1 CA186107 to M.J. Stampfer; P01 CA55075 to W.C. Willett; UM1 CA167552 to W.C. Willett; P50 CA127003 to C.S.F.; R01 CA137178 to A.T.C.; R01 CA151993 to S.O.; R35 CA197735 to S.O.; K07 CA190673 to R.N.; R01 CA137178 to A.T.C.; R01 CA151993 to S.O.; R35 CA197735 to S.O.; K07 CA190673 to R.N.; R03 CA176717 to X.Z.; and K07 CA188126 to X.Z.]; and by grants from the Project P Fund, The Friends of the Dana-Farber Cancer Institute, Bennett Family Fund, and the Entertainment Industry Foundation through National Colorectal Cancer Research Alliance. K.M. is supported by a grant from Program for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers from Japan Society for the Promotion of Science. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

REFERENCES

in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell. 2006; 9:199-207.


